Advanced in Angiosarcoma

Dr. Joshua M. Mammen

Surgical Oncology
Unmc Physicians
987400 Nebraska Medical Ctr, Unmc Physicians Nebraska M, 
Omaha, NE 
Accepting New Patients
Offers Telehealth
Advanced in Angiosarcoma
Unmc Physicians
987400 Nebraska Medical Ctr, Unmc Physicians Nebraska M, 
Omaha, NE 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joshua Mammen is a Surgical Oncologist in Omaha, Nebraska. Dr. Mammen is rated as an Advanced provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Merkel Cell Carcinoma, Melanoma, Eccrine Porocarcinoma, Lymphadenectomy, and Ureteroscopy. Dr. Mammen is currently accepting new patients.

His clinical research consists of co-authoring 27 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Surgical Oncology
Licenses
Surgery in TX
Hospital Affiliations
Bellevue Medical Center, LLC
The Nebraska Medical Center
Languages Spoken
English
American Sign Language
Burmese
French
Malayalam
Malayan
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 5 Less Insurance Carriers -

Locations

UNMC PHYSICIANS
987400 Nebraska Medical Ctr, Unmc Physicians Nebraska M, Omaha, NE 68198
Other Locations
UNMC PHYSICIANS
2500 Bellevue Medical Ctr Dr, Bellevue, NE 68123

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Biological, Radiation
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

27 Total Publications

International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma.
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma.
Journal: Annals of surgical oncology
Published: August 12, 2025
Similar Doctors
Distinguished in Angiosarcoma
Dr. Jessica E. Maxwell
Surgical Oncology
Distinguished in Angiosarcoma
Dr. Jessica E. Maxwell
Surgical Oncology

Unmc Physicians

111 N 175th St, Unmc Physicians Village Po, 
Omaha, NE 
 (11.1 miles away)
402-596-5600
Experience:
16+ years
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients

Jessica Maxwell is a Surgical Oncologist in Omaha, Nebraska. Dr. Maxwell has been practicing medicine for over 16 years and is rated as an Advanced provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Breast Cancer, Paget Disease of the Breast, and Lymphadenectomy. Dr. Maxwell is currently accepting new patients.

Distinguished in Angiosarcoma
Dr. James A. Reilly
General Surgery | Surgical Oncology
Distinguished in Angiosarcoma
Dr. James A. Reilly
General Surgery | Surgical Oncology
8111 Dodge St, Suite 263, 
Omaha, NE 
 (3.4 miles away)
402-354-8163
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Reilly is a General Surgeon and a Surgical Oncologist in Omaha, Nebraska. Dr. Reilly is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Angiosarcoma, Intraductal Papilloma, and Lymphadenectomy. Dr. Reilly is currently accepting new patients.

Advanced in Angiosarcoma
Dr. George W. Dittrick
Surgical Oncology | Emergency Medicine | General Surgery
Advanced in Angiosarcoma
Dr. George W. Dittrick
Surgical Oncology | Emergency Medicine | General Surgery

Physicians Clinic Inc

8111 Dodge St, Suite 263, 
Omaha, NE 
 (3.4 miles away)
402-354-8163
Languages Spoken:
English
See accepted insurances
Accepting New Patients

George Dittrick is a Surgical Oncologist and an Emergency Medicine provider in Omaha, Nebraska. Dr. Dittrick is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Familial Pancreatic Cancer, Pancreatic Cancer, Pancreatic Adenoma, Pancreatectomy, and Small Bowel Resection. Dr. Dittrick is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mammen's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile